Results 13,321-13,340 of 26,610 for speaker:David Cullinane

Public Accounts Committee: 2017 Annual Report of the Comptroller and Auditor General
Chapter 15: Hepatitis C Treatment in Ireland
Management of Medical Negligence (22 Nov 2018)

David Cullinane: Would Ms Tait know?

Public Accounts Committee: 2017 Annual Report of the Comptroller and Auditor General
Chapter 15: Hepatitis C Treatment in Ireland
Management of Medical Negligence (22 Nov 2018)

David Cullinane: At this point, may I commend Dr. Brian O'Mahony, the chief executive of the Irish Haemophilia Society? I know he has worked with Mr. Breslin and the HSE. The Irish Haemophilia Society has done major work for the people who suffered as a consequence of this medical negligence scandal. I spoke to a number of people who have been through the process and have been compensated, which is the...

Public Accounts Committee: 2017 Annual Report of the Comptroller and Auditor General
Chapter 15: Hepatitis C Treatment in Ireland
Management of Medical Negligence (22 Nov 2018)

David Cullinane: I thank Mr. Breslin. His response is appreciated. I will now deal with the report of the Comptroller and Auditor General, which is primarily why we are here. The insurance scheme is referenced in page 165 and the report notes that the HSE does not have a current estimate of future expenditure to be incurred on the scheme. Why is there no estimate?

Public Accounts Committee: 2017 Annual Report of the Comptroller and Auditor General
Chapter 15: Hepatitis C Treatment in Ireland
Management of Medical Negligence (22 Nov 2018)

David Cullinane: May I interrupt Ms Tait? The Comptroller and Auditor General referred to this in his report. Is he simply noting that there is no current estimate of the cost or is he saying that is a difficulty?

Public Accounts Committee: 2017 Annual Report of the Comptroller and Auditor General
Chapter 15: Hepatitis C Treatment in Ireland
Management of Medical Negligence (22 Nov 2018)

David Cullinane: There was no learning from the figure being unavailable. Was Mr. McCarthy noting that there was no estimated cost?

Public Accounts Committee: 2017 Annual Report of the Comptroller and Auditor General
Chapter 15: Hepatitis C Treatment in Ireland
Management of Medical Negligence (22 Nov 2018)

David Cullinane: The report of the Comptroller and Auditor General states that in 2012 the HSE estimates that between 20,000 and 30,000 people were infected by hepatitis C with around 10,000 individuals living with chronic infection at the end of 2009. Those figures were from nine years ago. Does the HSE have up-to-date figures? Are the figures much the same or have they changed?

Public Accounts Committee: 2017 Annual Report of the Comptroller and Auditor General
Chapter 15: Hepatitis C Treatment in Ireland
Management of Medical Negligence (22 Nov 2018)

David Cullinane: Professor McCormick mentioned the modelling study. Was that Europe-wide?

Public Accounts Committee: 2017 Annual Report of the Comptroller and Auditor General
Chapter 15: Hepatitis C Treatment in Ireland
Management of Medical Negligence (22 Nov 2018)

David Cullinane: It estimated that 29,500 people were affected.

Public Accounts Committee: 2017 Annual Report of the Comptroller and Auditor General
Chapter 15: Hepatitis C Treatment in Ireland
Management of Medical Negligence (22 Nov 2018)

David Cullinane: No. I am referring to the modelling study. I am looking on page 167 of the-----

Public Accounts Committee: 2017 Annual Report of the Comptroller and Auditor General
Chapter 15: Hepatitis C Treatment in Ireland
Management of Medical Negligence (22 Nov 2018)

David Cullinane: Therefore, there were two modelling studies.

Public Accounts Committee: 2017 Annual Report of the Comptroller and Auditor General
Chapter 15: Hepatitis C Treatment in Ireland
Management of Medical Negligence (22 Nov 2018)

David Cullinane: Professor McCormick might be able to help me with this. Paragraph 15.26 on page 167 of the Comptroller and Auditor General's report states, "A modelling study in hepatitis C prevalence in 2015 carried out for 28 EU countries estimated the number infected with the hepatitis C virus in Ireland at 29,500."

Public Accounts Committee: 2017 Annual Report of the Comptroller and Auditor General
Chapter 15: Hepatitis C Treatment in Ireland
Management of Medical Negligence (22 Nov 2018)

David Cullinane: How did the modelling study work? Is that an estimate?

Public Accounts Committee: 2017 Annual Report of the Comptroller and Auditor General
Chapter 15: Hepatitis C Treatment in Ireland
Management of Medical Negligence (22 Nov 2018)

David Cullinane: Reference to under-diagnosis and the national screening guideline for hepatitis C is made on page 168 of the Comptroller and Auditor General report. It stated that no national guidance for healthcare providers was developed. Is that still the case?

Public Accounts Committee: 2017 Annual Report of the Comptroller and Auditor General
Chapter 15: Hepatitis C Treatment in Ireland
Management of Medical Negligence (22 Nov 2018)

David Cullinane: The Comptroller and Auditor General might be able to help me with what is meant. Paragraph 15.29 states:With regard to reducing under-diagnosis, the HSE in collaboration with the Department of Health published the National Screening Guideline for Hepatitis Cin 2017. The guidelines acknowledged that while screening for hepatitis C had been ongoing in many settings, national guidance for...

Public Accounts Committee: 2017 Annual Report of the Comptroller and Auditor General
Chapter 15: Hepatitis C Treatment in Ireland
Management of Medical Negligence (22 Nov 2018)

David Cullinane: There is a contradiction here between the response Ms Tait has given and what the Comptroller and Auditor General has reported. Either national guidelines were in place for healthcare providers or they were not. It is either a factual observation by the Comptroller and Auditor General or it is wrong.

Public Accounts Committee: 2017 Annual Report of the Comptroller and Auditor General
Chapter 15: Hepatitis C Treatment in Ireland
Management of Medical Negligence (22 Nov 2018)

David Cullinane: I ask Ms Tait to supply a note on that. The Comptroller and Auditor General may be able to follow up on it and if he is satisfied that is the case, then there is a match. I do not see a match. If there is one, that is fine.

Public Accounts Committee: 2017 Annual Report of the Comptroller and Auditor General
Chapter 15: Hepatitis C Treatment in Ireland
Management of Medical Negligence (22 Nov 2018)

David Cullinane: Therefore, it has been put in place.

Public Accounts Committee: 2017 Annual Report of the Comptroller and Auditor General
Chapter 15: Hepatitis C Treatment in Ireland
Management of Medical Negligence (22 Nov 2018)

David Cullinane: Paragraph 15.31 of the Comptroller and Auditor General's report states:A strategy document produced by the then Eastern Regional Health Authority in 2004 set out recommendations to enhance prevention, treatment and surveillance of hepatitis C among infected people in the eastern region. The report was never published and an implementation plan was not developed. Why was it not published?

Public Accounts Committee: 2017 Annual Report of the Comptroller and Auditor General
Chapter 15: Hepatitis C Treatment in Ireland
Management of Medical Negligence (22 Nov 2018)

David Cullinane: Ms Tait does not know why.

Public Accounts Committee: 2017 Annual Report of the Comptroller and Auditor General
Chapter 15: Hepatitis C Treatment in Ireland
Management of Medical Negligence (22 Nov 2018)

David Cullinane: Does Mr. Connaghan know?